AirSculpt Technologies, Inc. (AIRS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AirSculpt Technologies, Inc. (AIRS) trades at $4.55 with AI Score 35/100 (Grade D). AirSculpt Technologies, Inc. provides body contouring services using its proprietary AirSculpt method. Market cap: $321.34M, Sector: Healthcare.
Price live · AI analysis from May 6, 2026AIRS stock analysis for 2026: Analysts have set a consensus price target of $4.50 for AirSculpt Technologies, Inc., suggesting 1.2% downside from the current price of $4.55. The AI MoonshotScore is 35/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
AIRS: 4/7 perspectives are bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →AirSculpt Technologies, Inc. (AIRS) Healthcare & Pipeline Overview
AirSculpt Technologies, Inc. specializes in minimally invasive body contouring through its AirSculpt procedure, offering fat removal and transfer services. Operating in the medical care facilities sector, the company differentiates itself with a proprietary technique and a focus on patient-specific customization, serving a growing market for aesthetic procedures.
What Is the Investment Thesis for AIRS?
AirSculpt Technologies presents a focused investment opportunity within the aesthetic medical services sector. The company's proprietary AirSculpt technology offers a differentiated approach to body contouring, potentially driving revenue growth through increased market penetration. With a gross margin of 63.5%, AirSculpt demonstrates strong pricing power and operational efficiency. Key value drivers include expanding its geographic footprint by opening new centers and increasing brand awareness through targeted marketing efforts. However, the company's negative profit margin of -7.7% raises concerns about profitability and cost management. The high beta of 2.80 indicates significant volatility, reflecting sensitivity to market fluctuations. Successful execution of its expansion strategy and improved cost controls are crucial for realizing the company's growth potential. Investors should closely monitor the company's ability to achieve profitability and manage its operational expenses.
Based on FMP financials and quantitative analysis
AIRS Key Highlights
- AirSculpt Technologies operates 19 centers across 15 states as of March 2022, indicating a growing geographic presence.
- The company's gross margin of 63.5% demonstrates strong pricing power and efficient service delivery.
- AirSculpt's proprietary AirSculpt procedure offers a minimally invasive alternative to traditional liposuction, differentiating it in the market.
- The company's market capitalization is $0.12 billion, reflecting its current valuation in the market.
- AirSculpt's beta of 2.80 indicates high volatility compared to the broader market.
Who Are AIRS's Competitors?
AIRS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.28 | +0.64% | $31.56B | 84 |
| ALGN Align Technology, Inc. | $188.39 | +2.10% | $13.49B | 88 |
| COO The Cooper Companies, Inc. | $72.77 | -1.93% | $14.19B | 77 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AIRS's Key Strengths?
- Proprietary AirSculpt technology.
- Minimally invasive procedure reduces recovery time.
- Customized treatment plans tailored to individual needs.
- Strong brand reputation in body contouring.
What Are AIRS's Weaknesses?
- Negative profit margin raises concerns about profitability.
- Limited geographic presence compared to larger competitors.
- High beta indicates significant market volatility.
- Reliance on discretionary spending, making it vulnerable to economic downturns.
What Could Drive AIRS Stock Higher?
- Expansion into new geographic markets, increasing revenue potential.
- Marketing and brand awareness campaigns to attract new customers.
- Development and introduction of new body contouring procedures.
- Strategic partnerships with other healthcare providers.
What Are the Key Risks for AIRS?
- Negative return on equity (-12.4%) — the business is not currently generating profit on shareholder capital.
- Economic downturns impacting discretionary spending on aesthetic procedures.
- Increased competition from traditional liposuction and other aesthetic services.
- Regulatory changes affecting the body contouring industry.
- Negative publicity or lawsuits related to procedures.
- High beta indicates significant market volatility.
What Are the Growth Opportunities for AIRS?
- Geographic Expansion: AirSculpt has the opportunity to expand its geographic footprint by opening new centers in underserved markets. The market for aesthetic procedures is growing nationally, and strategic expansion into new regions can drive revenue growth. Each new center represents a potential revenue stream, and the company's proven business model can be replicated in new locations. The timeline for opening new centers is dependent on securing suitable locations and obtaining necessary regulatory approvals. Successful expansion requires effective marketing and brand awareness campaigns to attract new customers in each market.
- Service Line Expansion: AirSculpt can expand its service offerings by introducing new procedures and treatments that complement its existing body contouring services. This could include non-surgical skin tightening, cellulite reduction, or other aesthetic treatments. Expanding the service line can attract a broader range of customers and increase revenue per customer. The market for non-surgical aesthetic treatments is growing rapidly, presenting a significant opportunity for AirSculpt. The timeline for introducing new services depends on research and development, clinical trials, and regulatory approvals.
- Marketing and Brand Awareness: AirSculpt can invest in marketing and brand awareness campaigns to attract new customers and increase market share. This could include online advertising, social media marketing, and partnerships with influencers. Increased brand awareness can drive more traffic to AirSculpt centers and increase the number of consultations and procedures. The market for aesthetic procedures is highly competitive, and effective marketing is essential for success. The timeline for implementing marketing campaigns is ongoing, with continuous optimization and adaptation to market trends.
- Technology Innovation: AirSculpt can invest in research and development to further enhance its AirSculpt technology and develop new and improved techniques. This could include advancements in precision, safety, and patient comfort. Technological innovation can differentiate AirSculpt from its competitors and attract customers seeking the most advanced and effective treatments. The market for aesthetic procedures is constantly evolving, and innovation is essential for maintaining a competitive edge. The timeline for technological innovation is long-term, with ongoing research and development efforts.
- Strategic Partnerships: AirSculpt can form strategic partnerships with other healthcare providers, such as dermatologists, plastic surgeons, and medical spas, to expand its reach and referral network. Partnerships can provide access to new customers and markets, and can enhance AirSculpt's credibility and reputation. The market for aesthetic procedures is fragmented, and partnerships can help AirSculpt consolidate its position. The timeline for forming strategic partnerships depends on identifying suitable partners and negotiating mutually beneficial agreements.
What Opportunities Does AIRS Have?
- Expansion into new geographic markets.
- Introduction of new body contouring procedures.
- Increased marketing and brand awareness efforts.
- Strategic partnerships with other healthcare providers.
What Threats Does AIRS Face?
- Competition from traditional liposuction and other aesthetic procedures.
- Economic downturns impacting discretionary spending.
- Regulatory changes affecting the body contouring industry.
- Negative publicity or lawsuits related to procedures.
What Are AIRS's Competitive Advantages?
- Proprietary AirSculpt technology provides a differentiated service offering.
- Established brand reputation for minimally invasive body contouring.
- Network of strategically located body contouring centers.
- Skilled surgeons and medical staff trained in the AirSculpt procedure.
What Does AIRS Do?
AirSculpt Technologies, Inc., founded in 2012 and headquartered in Miami Beach, Florida, operates as a holding company for EBS Intermediate Parent LLC. The company provides body contouring services, primarily through its patented AirSculpt procedure, a minimally invasive method for removing unwanted fat. AirSculpt distinguishes itself from traditional liposuction by offering a more precise and less invasive approach. The company's services include fat removal from various treatment areas and fat transfer procedures to enhance areas like the breasts, buttocks (Power BBL), and hips (Hip Flip). AirSculpt also offers breast enhancement procedures (Up a Cup). As of March 10, 2022, AirSculpt Technologies operated 19 centers across 15 states, reflecting its expanding geographic footprint within the United States. The company focuses on providing customized body contouring solutions tailored to individual patient needs and preferences. AirSculpt's business model centers around direct-to-consumer marketing and a high-touch patient experience, emphasizing safety and natural-looking results. The company aims to capture a significant share of the growing market for aesthetic procedures by offering a differentiated and patient-centric approach to body contouring.
What Products and Services Does AIRS Offer?
- Provides minimally invasive body contouring services.
- Utilizes the proprietary AirSculpt procedure for fat removal.
- Offers fat transfer procedures to enhance various body areas.
- Operates body contouring centers across multiple states.
- Provides customized treatment plans tailored to individual patient needs.
- Focuses on a direct-to-consumer marketing approach.
- Offers procedures like Power BBL, Up a Cup, and Hip Flip.
How Does AIRS Make Money?
- Generates revenue through fees for body contouring procedures.
- Operates on a direct-to-consumer model, attracting clients through marketing and consultations.
- Employs skilled surgeons and medical staff to perform AirSculpt procedures.
What Industry Does AIRS Operate In?
AirSculpt Technologies operates within the medical care facilities industry, part of the broader healthcare sector. This industry is characterized by increasing demand for aesthetic procedures and a growing focus on minimally invasive techniques. The market for body contouring is expanding, driven by factors such as rising disposable incomes and increasing awareness of aesthetic options. AirSculpt competes with traditional plastic surgery practices and other providers of non-invasive and minimally invasive cosmetic procedures. The company's success depends on its ability to differentiate itself through its proprietary technology, patient experience, and marketing effectiveness. The industry is also subject to regulatory oversight and evolving consumer preferences.
Who Are AIRS's Key Customers?
- Individuals seeking minimally invasive fat removal.
- Patients desiring body contouring and enhancement.
- Consumers looking for alternatives to traditional liposuction.
AirSculpt Technologies, Inc. Financial Trajectory
AirSculpt Technologies, Inc. (AIRS) reported $39.4M in revenue for Q1 2026, reflecting 17.8% growth compared to the prior quarter. The company recorded a net loss of $2.4M, with diluted EPS of $-0.03. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, AIRS averaged $-0.04 in diluted EPS.
Company Profile
AirSculpt Technologies, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Yogesh Jashnani. AIRS has traded publicly since 2021.
How AirSculpt Technologies, Inc. Is Valued
AirSculpt Technologies, Inc. carries a market capitalization of $321.34M, placing it in the small-cap category. Relative to its peer group, AIRS's quantitative score of 35/100 is below the peer average of 75/100.
ROE -12%Key Financial Metrics
Return on equity for AirSculpt Technologies, Inc. stands at -12.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.75 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
AirSculpt Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.37 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project AirSculpt Technologies, Inc. revenue of about $153.3M for fiscal 2026, with EPS near $-0.04.
Net sellingInsider Activity
Over the past six months, AirSculpt Technologies, Inc. insiders filed 27 SEC Form 4 transactions — 5 sales and 22 purchases. On net that is roughly 3.7M shares disposed (about $1.9M), a signal worth weighing alongside the fundamentals.
AIRS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary AirSculpt technology.
- Minimally invasive procedure reduces recovery time.
- Customized treatment plans tailored to individual needs.
- Strong brand reputation in body contouring.
Bear Case
- Negative profit margin raises concerns about profitability.
- Limited geographic presence compared to larger competitors.
- High beta indicates significant market volatility.
- Reliance on discretionary spending, making it vulnerable to economic downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $39M | -$2M | -$0.03 |
| Q4 2025 | $33M | $1M | $0.02 |
| Q3 2025 | $35M | -$10M | -$0.15 |
| Q2 2025 | $44M | -$591,000 | -$0.01 |
Based on FMP financials and quantitative analysis
AIRS Latest News
-
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions
businesswire.com · Jun 16, 2026
-
Is Prisma AIRS Becoming Palo Alto Networks' Fastest Growth Engine?
zacks.com · Jun 10, 2026
-
AirSculpt Technologies Announces Participation in Upcoming Investor Conferences
globenewswire.com · May 27, 2026
-
AirSculpt Technologies Sees Sales Rebound, GLP-1 Tailwind for Body Contouring Growth
marketbeat.com · May 19, 2026
AIRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AIRS.
Price Targets
Consensus target: $4.50
AIRS MoonshotScore
What does this score mean?
The MoonshotScore rates AIRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions
Is Prisma AIRS Becoming Palo Alto Networks' Fastest Growth Engine?
AirSculpt Technologies Announces Participation in Upcoming Investor Conferences
AirSculpt Technologies Sees Sales Rebound, GLP-1 Tailwind for Body Contouring Growth
Leadership: Yogesh Jashnani
CEO
Yogesh Jashnani serves as the CEO of AirSculpt Technologies, Inc. His background includes experience in managing and scaling businesses within the healthcare and consumer sectors. He has a proven track record of driving revenue growth and improving operational efficiency. Jashnani's expertise lies in strategic planning, marketing, and business development. He is responsible for overseeing all aspects of AirSculpt's operations, including marketing, sales, and clinical services. His leadership is focused on expanding the company's geographic footprint and enhancing its brand reputation.
Track Record: Under Yogesh Jashnani's leadership, AirSculpt Technologies has focused on expanding its presence in key markets and enhancing its marketing efforts to drive brand awareness. He has overseen the implementation of new technologies and procedures to improve patient outcomes and satisfaction. Jashnani has also focused on building a strong team of medical professionals and support staff to deliver high-quality services. His strategic decisions have contributed to the company's growth and market position.
What Investors Ask About AirSculpt Technologies, Inc. (AIRS) — Healthcare
What does AirSculpt Technologies, Inc. do?
AirSculpt Technologies, Inc. specializes in providing minimally invasive body contouring services through its proprietary AirSculpt procedure. This procedure offers a less invasive alternative to traditional liposuction, focusing on precise fat removal and transfer techniques. The company operates a network of centers across the United States, offering customized treatment plans tailored to individual patient needs. AirSculpt's business model centers around direct-to-consumer marketing and a high-touch patient experience, emphasizing safety and natural-looking results. The company aims to capture a significant share of the growing market for aesthetic procedures by offering a differentiated and patient-centric approach to body contouring.
What do analysts say about AIRS stock?
Analyst coverage of AirSculpt Technologies, Inc. is still emerging, with limited consensus available. Key valuation metrics, such as price-to-earnings and price-to-sales ratios, are influenced by the company's current negative profit margin. Growth considerations center around the company's ability to expand its geographic footprint, increase brand awareness, and improve operational efficiency. Investors should closely monitor the company's financial performance and strategic initiatives to assess its long-term growth potential. Analyst ratings and price targets may vary depending on individual firms' research methodologies and investment perspectives. It is important to conduct thorough due diligence and consider multiple sources of information before making any investment decisions.
What are the main risks for AIRS?
AirSculpt Technologies, Inc. faces several risks inherent to the aesthetic medical services industry. Economic downturns could reduce discretionary spending on body contouring procedures, impacting revenue. Increased competition from traditional liposuction and other aesthetic services could erode market share. Regulatory changes affecting the body contouring industry could increase compliance costs and limit service offerings. Negative publicity or lawsuits related to procedures could damage the company's reputation and financial performance. Additionally, the company's high beta indicates significant market volatility, making it susceptible to broader market fluctuations. Effective risk management and mitigation strategies are crucial for the company's long-term success.
What are the key factors to evaluate for AIRS?
AirSculpt Technologies, Inc. (AIRS) holds an AI score of 35/100 (low). Analysts target $4.50 (-1%). Not financial advice.
How frequently does AIRS data refresh on this page?
AIRS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AIRS's recent stock price performance?
AirSculpt Technologies, Inc. (AIRS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AirSculpt technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIRS overvalued or undervalued right now?
Valuing AirSculpt Technologies, Inc. (AIRS) requires multiple metrics. Analysts target $4.50 (-1%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AIRS?
Before investing in AirSculpt Technologies, Inc. (AIRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of the latest available reporting period.